(s)-2-Hydroxy-4,4-dimethylpentanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (s)-2-Hydroxy-4,4-dimethylpentanoic acid
• 英文别名: (2S)-2-hydroxy-4,4-dimethylpentanoic acid
• 化学式: C₇H₁₄O₃
• 分子量: 146.18
• InChiKey: OPBFFNZNNJKRCS-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Cryptophycin compound
  申请人：——

  公开号：US20020065261A1

  公开（公告）日：2002-05-30

  The present invention provides antitumor methods, formulations, and compounds comprising a cryptophycin.

  本发明提供了包含一种隐花链霉素的抗肿瘤方法、配方和化合物。
• Inhibitors of cathepsin S
  申请人：Liu Hong

  公开号：US20050107368A1

  公开（公告）日：2005-05-19

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了一种选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当存在至少一种其他蛋白酶同工酶时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗主体的疾病状态的方法。
• INHIBITORS OF CATHEPSIN S
  申请人：Liu Hong

  公开号：US20070259873A1

  公开（公告）日：2007-11-08

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了一种选择性抑制cathepsin S的化合物、组合物和方法。在一个优选方面，当存在至少另一种cathepsin同工酶时，选择性地抑制cathepsin S。本发明还提供了通过选择性抑制cathepsin S治疗主体的疾病状态的方法。
• IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS
  申请人：Zhuo Jincong

  公开号：US20080167287A1

  公开（公告）日：2008-07-10

  The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

  本发明涉及imidazo[1,2-b][1,2,4]三嗪和imidazo[1,2-a]嘧啶，以及其药物组合物，它们是c-Met抑制剂，并且在治疗癌症和与激酶通路失调相关的其他疾病中有用。
• GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Lin Songnian

  公开号：US20110281795A1

  公开（公告）日：2011-11-17

  Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

  本发明揭示了糖高原受体拮抗剂化合物。该化合物可用于治疗2型糖尿病及相关疾病。此外，还包括制药组合物和治疗方法。